We are excited to announce that Cour Pharmaceuticals, a pioneering company in our portfolio, has been recognized as one of the top 15 biotech companies of 2024 by Fierce Biotech.

Cour Pharmaceuticals earned this prestigious accolade due to its pioneering work in antigen-specific tolerance therapies aimed at treating autoimmune diseases. By leveraging cutting-edge science, Cour is advancing a novel approach to disease treatment that could potentially transform how autoimmune conditions are managed and treated.

As investors, we are thrilled to see Cour Pharmaceuticals receive this recognition and are excited about the future of their groundbreaking work in shaping the future of care.

Read the full article by Fierce Biotech to learn more about Cour Pharmaceuticals and the other biotech companies that are driving the future of healthcare innovation.